Expansion of endogenous T cells in CSF of pediatric CNS tumor patients undergoing locoregional delivery of IL13R〿2-targeting CAR T cells: an interim analysis.

Outcomes for pediatric brain tumor patients remain poor, and there is optimism that chimeric antigen receptor (CAR) T cell therapy can improve prognosis. Here, we present interim results from the first six pediatric patients treated on an ongoing phase I clinical trial (NCT04510051) of IL13BBζ-CAR T cells delivered weekly into the lateral cerebral ventricles, identifying clonal expansion of endogenous CAR-negative CD8

Déclaration de conflit d'intérêts

Statement of Competing Interests C.E.B., S.J.P., and S.J.F. report personal fees, patent royalties, and research support from Mustang Bio. C.E.B., S.J.F., and B.B. also have a patent for CAR T cell delivery pending and with royalties paid from Mustang Bio. N.E.B. receives compensation from DeepCell. S.J.P. is also a scientific advisor and/or receives royalties from Imugene Ltd, Bayer, Adicet Bio, and Celularity. Additional Declarations: Yes there is potential Competing Interest. C.E.B., S.J.P., and S.J.F. report personal fees, patent royalties, and research support from Mustang Bio. C.E.B., S.J.F., and B.B. also have a patent for CAR T cell delivery pending and with royalties paid from Mustang Bio. N.E.B. receives compensation from DeepCell. S.J.P. is also a scientific advisor and/or receives royalties from Imugene Ltd, Bayer, Adicet Bio, and Celularity.